Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
adsCLkdH0C3SRFhn
Listen
